drugset / Trial / NCT00724386

Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer

NCT00724386

Phase 1 Completed 26 enrolled University of Chicago Amgen · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The goal of this study is to determine the feasibility based on toxicity and response rate of giving paclitaxel weekly with concomitant every-other week radiotherapy to limit skin toxicity. This study will also seek to determine the maximally tolerated dose of Navelbine added to this combination when followed by Filgrastim and the dose-limiting toxicities of this regimen.

Timeline

Start
1999-06
Primary completion
2005-10
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Paclitaxel Small molecule Intravenous
Subject Vinorelbine Small molecule Intravenous
Background filgrastim Protein / enzyme biologic Other

Indications